32 results
8-K
EX-99.2
ANNX
Annexon Inc
20 Dec 23
Regulation FD Disclosure
5:17pm
complement inhibitor that we believe can have meaningful impact on a range of autoimmune conditions,” said Ted Yednock, Ph.D., chief innovation officer
8-K
EX-99.1
if5pojaf4p027ce
9 Nov 21
Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
4:16pm
8-K
t9lysa0g9w
4 Oct 21
Departure of Directors or Certain Officers
4:06pm
8-K
EX-99.1
e8jqa7
4 Oct 21
Departure of Directors or Certain Officers
4:06pm
DEF 14A
zdjm1uy7cgd7jtrvj 8q
22 Apr 21
Definitive proxy
4:06pm